Pharmaceutical companies should be required to regularly report whether there’s a link between drug-pricing strategies and executive-compensation plans, according to a shareholder group.
The Interfaith Center on Corporate Responsibility, a coalition of institutional investors with more than $400 billion of assets, said in a statement Wednesday that it submitted proposals for inclusion at the 2018 annual meetings of Abbvie Inc., Amgen Inc., Biogen Inc., Bristol Myers Squibb Co. and Eli Lilly & Co.
“An executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy,” the group said in the statement. “The investors view executive incentive programs as a governance tool designed to ensure adequate oversight of risk and alignment of corporate strategies with mission.”
All of the annual bonuses for the chief executive officers of the five companies were tied in part to revenue and earnings in their most recent fiscal years, proxy filings show. The average awarded pay for the CEOs was about $19.2 million, according to the Bloomberg Pay Index.
Lauren Zierke, a spokeswoman for Eli Lilly, said the company shares the coalition’s concerns about the price of medications for patients.
The drug maker is working to “identify solutions so medicine is accessible and affordable to those who need it,” she said in an emailed statement. “We have had a productive relationship and dialog with ICCR over time and will continue to engage with them.”
Spokespeople for the other pharmaceutical companies didn’t immediately reply to messages seeking comment.
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
